ATE225178T1 - Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände - Google Patents

Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände

Info

Publication number
ATE225178T1
ATE225178T1 AT97928369T AT97928369T ATE225178T1 AT E225178 T1 ATE225178 T1 AT E225178T1 AT 97928369 T AT97928369 T AT 97928369T AT 97928369 T AT97928369 T AT 97928369T AT E225178 T1 ATE225178 T1 AT E225178T1
Authority
AT
Austria
Prior art keywords
chelates
treatment
free radicals
conditions caused
metal
Prior art date
Application number
AT97928369T
Other languages
English (en)
Inventor
Jan Olof Gustav Karlsson
Per Jynge
Robertson Towart
Original Assignee
Amersham Health As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Health As filed Critical Amersham Health As
Application granted granted Critical
Publication of ATE225178T1 publication Critical patent/ATE225178T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Manufacture And Refinement Of Metals (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Semiconductor Lasers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97928369T 1996-06-24 1997-06-24 Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände ATE225178T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
PCT/GB1997/001722 WO1997049409A1 (en) 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radicals induced conditions

Publications (1)

Publication Number Publication Date
ATE225178T1 true ATE225178T1 (de) 2002-10-15

Family

ID=10795775

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97928368T ATE228361T1 (de) 1996-06-24 1997-06-24 Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen
AT97928369T ATE225178T1 (de) 1996-06-24 1997-06-24 Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97928368T ATE228361T1 (de) 1996-06-24 1997-06-24 Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen

Country Status (14)

Country Link
US (2) US6147094A (de)
EP (2) EP0936915B1 (de)
JP (2) JP4359651B2 (de)
CN (2) CN1228703A (de)
AT (2) ATE228361T1 (de)
AU (2) AU720621B2 (de)
BR (1) BR9709942A (de)
CA (2) CA2259150A1 (de)
DE (2) DE69717447T2 (de)
GB (1) GB9613182D0 (de)
IL (1) IL127733A0 (de)
NO (2) NO985917L (de)
NZ (2) NZ333315A (de)
WO (2) WO1997049390A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69826528T2 (de) * 1997-12-23 2006-02-23 Amersham Health As Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
KR20100075503A (ko) 1999-10-01 2010-07-02 디엠아이 바이오사이언시스, 인크 금속 결합 화합물 및 그의 용도
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
PT1744764E (pt) 2004-04-22 2012-08-30 Celator Pharmaceuticals Inc Formulações lipossómicas de agentes antraciclina e análogos de citidina
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
KR101678865B1 (ko) 2007-12-14 2016-11-23 플레드파르마 에이비 암의 치료에 사용하기 위한 화합물들
WO2011004325A1 (en) * 2009-07-06 2011-01-13 Pledpharma Ab Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
HRP20200793T1 (hr) 2011-05-09 2020-10-16 Mayo Foundation For Medical Education And Research Liječenje raka
AU2012364227B2 (en) 2012-01-05 2017-12-07 Egetis Therapeutics Ab Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
CA2917407C (en) 2012-10-01 2023-03-14 Mayo Foundation For Medical Education And Research Complexes containing albumin-containing nanoparticles and antibodies to treat cancer
KR20150080616A (ko) 2012-11-02 2015-07-09 플레드파르마 에이비 암 치료 방법
CA2950926A1 (en) 2014-06-13 2015-12-17 Mayo Foundation For Medical Education And Research Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas
JP6600651B2 (ja) 2014-06-16 2019-10-30 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 骨髄腫の治療
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (de) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research Verfahren zur behandlung von krebs mit interferon
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CA3018340A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
EP3432926A4 (de) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Verfahren zur verminderung der toxizität eines chemotherapeutikums
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3506950A1 (de) 2016-09-01 2019-07-10 Mayo Foundation for Medical Education and Research Gegen t-zell-karzinome gerichtete verfahren und zusammensetzungen
JP7525999B2 (ja) 2016-09-01 2024-07-31 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ キャリアー-pd-l1結合剤組成物及び癌を処置する為にそれを使用する方法
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
RU2756892C2 (ru) 2016-09-06 2021-10-06 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
EP3509635A1 (de) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Verfahren zur behandlung von dreifach negativem brustkrebs unter verwendung von zusammensetzungen aus antikörpern und trägerproteinen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Also Published As

Publication number Publication date
NO985916D0 (no) 1998-12-17
EP0910360B1 (de) 2002-11-27
BR9709942A (pt) 1999-08-10
AU720570B2 (en) 2000-06-08
AU3268997A (en) 1998-01-14
NZ333357A (en) 2000-08-25
US6147094A (en) 2000-11-14
NO985916L (no) 1999-01-25
US6258828B1 (en) 2001-07-10
JP4359651B2 (ja) 2009-11-04
NO985917D0 (no) 1998-12-17
JP4162263B2 (ja) 2008-10-08
IL127733A0 (en) 1999-10-28
EP0936915B1 (de) 2002-10-02
AU720621B2 (en) 2000-06-08
NZ333315A (en) 2000-07-28
NO985917L (no) 1999-01-25
AU3268897A (en) 1998-01-14
WO1997049409A1 (en) 1997-12-31
CA2258299A1 (en) 1997-12-31
GB9613182D0 (en) 1996-08-28
ATE228361T1 (de) 2002-12-15
DE69717447T2 (de) 2003-09-11
JP2000513351A (ja) 2000-10-10
DE69716104D1 (de) 2002-11-07
EP0936915A1 (de) 1999-08-25
JP2000514044A (ja) 2000-10-24
CN1228694A (zh) 1999-09-15
CA2259150A1 (en) 1997-12-31
EP0910360A1 (de) 1999-04-28
DE69717447D1 (de) 2003-01-09
CN1228703A (zh) 1999-09-15
WO1997049390A1 (en) 1997-12-31
DE69716104T2 (de) 2003-05-28

Similar Documents

Publication Publication Date Title
DE69716104D1 (de) Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände
ATE277038T1 (de) Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
DE69703294D1 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
MX9705235A (es) Inhibidores de calpaina y/o catepsina b de oxazolidina substituida.
DE69942680D1 (de) Verfahren und Zusammensetzungen zur Prävention und Behandlung von Anämie
ATE332708T1 (de) Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DE69834658D1 (de) Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität
SG152907A1 (en) Combinations for the treatment of inflammatory disorders
DE69934590D1 (de) Verbindung und verfahren zur bekämpfung und/oder behandlung der allergie
DE69807115D1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE602004031356D1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
DE69413829D1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
DE69938036D1 (de) Mittel und verfahren zum schutz, zur behandlung und zur reparatur von bindegewebe
ATE485818T1 (de) Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
ATE273702T1 (de) Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties